Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody
| Status: | Recruiting |
|---|---|
| Conditions: | Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 19 - 70 |
| Updated: | 1/20/2018 |
| Start Date: | September 12, 2017 |
| End Date: | December 31, 2018 |
| Contact: | Karen Murphy, BS, CCRC |
| Email: | kmurphy@bernsteincrc.com |
| Phone: | 5133541746 |
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody
Study to determine the efficacy of benralizumab when compared to placebo in patients with
chronic hives that do not respond to antihistamine treatment
chronic hives that do not respond to antihistamine treatment
Subjects with chronic hives that do not respond to antihistamine treatment and have hives of
unknown cause will be eligible. Subjects who meet the inclusion/exclusion criteria after the
run-in phase will receive 3 doses of study medication. The study also involved blood draws
and a punch biopsy of a hive
unknown cause will be eligible. Subjects who meet the inclusion/exclusion criteria after the
run-in phase will receive 3 doses of study medication. The study also involved blood draws
and a punch biopsy of a hive
Inclusion Criteria:
- hives for over 6 weeks of unknown cause hives most days of the despite use of
antihistamines
Exclusion Criteria:
- hives due to known reasons history of cancer pregnant or nursing History of HIV or
Hepatitis recent parasitic infection currently or have received treatment with a
monoclonal antibody
We found this trial at
1
site
Cincinnati, Ohio 45231
Principal Investigator: Jonathan Bernstein, MD
Phone: 513-354-1746
Click here to add this to my saved trials
